ArticleJournal of clinical & translational endocrinology2015
Calcitriol treatment in metabolic bone disease of prematurity with elevated parathyroid hormone: A preliminary study.
Article in Journal of clinical & translational endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Prevention and management of metabolic bone disease of prematurity: a systematic review.Journal of perinatology : official journal of the California Perinatal Association · 2026Pooled it
- Article
- Interventions for metabolic bone disease of prematurity: A systematic review and meta-analysis.Metabolism open · 2026Article
- Biochemical markers for metabolic bone disease in preterm infants: insights from a structured Bone Health Programme in the Middle East.BMJ paediatrics open · 2025Article
- Invited Mini Review Metabolic Bone Disease of Prematurity: Overview and Practice Recommendations.Hormone research in paediatrics · 2025Review
- Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews.Journal of clinical medicine · 2022Article
- A Quality Improvement Project to Decrease Fractures Secondary to Metabolic Bone Disease of Prematurity.Pediatric quality & safetyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the association of calcitriol treatment with the change in parathyroid hormone (PTH) and biochemical markers of bone disease in infants with metabolic bone disease of prematurity (MBD) and secondary hyperparathyroidism. STUDY
designThis retrospective chart review examined serum intact PTH, serum calcium (Ca), serum phosphorus (P), serum alkaline phosphatase (APA), urine calcium/creatinine (UCa/Cr), and tubular reabsorption of phosphate (TRP) in 32 infants prior to and following calcitriol treatment for MBD with PTH >100 pg/ml. 25-hydroxyvitamin D concentrations were recorded.
resultsFollowing calcitriol treatment, PTH decreased from median (min/max) 220 (115/593) to 25 (3/259) pg/ml,
conclusionImprovements in MBD markers and lack of serious adverse effects suggest calcitriol may be a treatment option in infants with MBD and secondary hyperparathyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.